Intravenous Sirolimus Shows Tolerability, Early Efficacy in Malignant PEComa

#1

I find this an interesting paper because its one of the few instances of intravenous rapamycin delivery I’ve come across. It seems like an approach like this may be valuable to investigate for longevity at some point.

Intravenous sirolimus (albumin bound, SRL-HSA) was well tolerated and elicited durable responses in patients with malignant perivascular epithelioid cell tumors (PEComa), according to findings from a phase 1b trial (NCT05625919) presented during the 2025 ESMO Sarcoma and Rare Cancers Congress.1

Reference

Niu X, Zhang X, Guo J, et al. 66MO Intravenous sirolimus (albumin bound, SRL-HSA) in malignant perivascular epithelioid cell tumors (PEComas): A multicenter, open label, phase Ib trial. ESMO Open. 2025;10(suppl 3):104380. doi:10.1016/j.esmoop.2025.104380

1 Like
#2

The albumin binding seems to create some superior characteristics, sold as Fyarro:

image
image848×498 21.4 KB

Nonclinical studies demonstrated significant pharmacodynamic improvement over oral mTOR inhibitors, including1,3:*

  • Enhanced bioavailability

  • Higher tumor drug concentrations

  • Increased mTOR target suppression

  • Stronger antitumor activity

Nonclinical data may not correlate with clinical outcomes.

AUC=area under the curve; IV=intravenous; mTOR=mechanistic target of rapamycin; UMUC3=University of Michigan-Urothelial Carcinoma-3.

1 Like
#3

Not New…

This was posted over two years ago…

Was around $7,000.00 per 100mg

Do not see many purchasing this for longevity use.

1 Like